After trading low on the day of its Q3FY25 results announcement, the shares showed positive momentum today by trading over 2% ...

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which ...

US formulation sales for Zydus Life during the quarter stood at $285 million, which is a growth of 29% on a year-on-year ...

Zydus Lifesciences Ltd share price was down by -3.65% from the previous closing price of ₹957.60. Who are peers of Zydus Lifesciences Ltd? The peers of Zydus Lifesciences Ltd are Sun ...

Zydus Lifesciences share prices showed an increase of more than 2 per cent during the early market hours, following the release of its Q3FY25 results the previous day.  For the relevant quarter, it ...

each (“Equity Shares”) of Zydus Lifesciences Limited (hereinafter referred as “the Company”) at a price of INR 1,005/- (Indian Rupees one thousand and five only) per Equity Share for an ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

Ahead of the market opening on Friday, February 7, analysts from domestic brokerages have recommended several stocks for ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

On 27th July 2011, Cadila Healthcare announced that its 100% subsidiary Zydus Animal Health Limited (AHL) has signed a Share Purchase ... where there are real-life situations of disease exposure ...